X

Multiple Myeloma

Multiple Myeloma

Combined Immune Score Predicts the Prognosis of Newly Diagnosed Multiple Myeloma Patients in the Bortezomib-Based Therapy Era

This study investigated the effect of a combined immune score including the lymphocyte-to-monocyte ratio and uninvolved immunoglobulin levels on the prognosis of newly diagnosed multiple myeloma...

Medicine
10/15/2021
Younger Age at Diagnosis May Predict Higher VTE Risk in Patients With Multiple Myeloma

Among younger patients with multiple myeloma and those with a high white cell count, higher-intensity thromboprophylaxis may be necessary for reducing the risk of venous thromboembolism.

Cancer Therapy Advisor
10/14/2021
Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone Alone in Newly Diagnosed Multiple Myeloma

A significant improvement in progression-free survival was observed with daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone...

The Lancet Oncology
10/13/2021

Salvage Autologous Stem Cell Transplantation May Improve Outcomes for Relapsed/Refractory Multiple Myeloma

Salvage therapy with high-dose chemotherapy followed by ASCT may lead to long-term improvements in survival for MM in some patients.

Hematology Advisor
10/12/2021
Effect of EPA on Hsp90 and GRα Protein Expression in Multiple Myeloma Drug-Resistant Cells

Scientists test the cytotoxic effects of EPA alone or EPA + Dexamethasone in MM.1R and investigate whether DHA can induce apoptosis and reverse acquired glucocorticoid resistance in MM.1R.

BMC Cancer
10/03/2021
Comparison Between Tumour Metabolism Derived from 18F-FDG PET/CT and Accurate Cytogenetic Stratification in Newly Diagnosed Multiple Myeloma Patients

This study examines the correlation between the new LP score and PET data among patients newly diagnosed for MM or secreting plasmacytoma...

Quantitative Imaging in Medicine and Surgery
10/01/2021
Tissue-Resident Macrophages Promote Early Dissemination of Multiple Myeloma via IL-6 and TNFα

Researchers propose that egress of myeloma cells from BM is regulated by localized inflammation in foci, driven in part by CD169+ MPs.

Blood Advances
09/22/2021
Pathophysiological Role of Calcium Channels and Transporters in the Multiple Myeloma

Research summarizes the expression, localization and pathophysiological role of some essential calcium channels and transporters...

Cell Communication and Signaling
09/27/2021
Maintenance Daratumumab After Initial Therapy for Newly Diagnosed Multiple Myeloma

Scientists significantly prolonged progression-free survival with maintenance daratumumab vs observation following induction and consolidation with or without daratumumab in addition to ASCT...

The ASCO Post
09/28/2021
Single Cell RNA-seq Data and Bulk Gene Profiles Reveal a Novel Signature of Disease Progression in Multiple Myeloma

Scientists complete a comprehensive analysis of scRNA-seq data and bulk gene expression profiles to reveal the development map of human MM cells...

Cancer Cell International
09/25/2021
Prognostic Importance of Extramedullary Lesions in Multiple Myeloma

Researchers conducting a retrospective study identified extramedullary lesions as a possible indicator of poor prognosis in patients with MM treated in the first line with bortezomib. 

Cancer Therapy Advisor
09/22/2021
Targeting The Methyltransferase SETD8 Impairs Tumor Cell Survival and Overcomes Drug Resistance Independently of p53 Status in Multiple Myeloma

Investigators showed that SETD8 inhibition is strongly synergistic with melphalan and may overcome resistance to this alkylating agent widely used in MM treatment.

Clinical Epigenetics
09/16/2021
Subcutaneous Daratumumab Added to Pomalidomide Plus Dexamethasone Improves Progression-Free Survival in Multiple Myeloma

The phase III APOLLO trial has shown significantly improved PFS with the addition of subcutaneous daratumumab to oral pomalidomide/dexamethasone in previously treated MM.

The ASCO Post
09/10/2021
Updated Safety and Efficacy of CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

A single dose of ciltacabtagene autoleucel yields early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Cancer Therapy Advisor
09/15/2021
How Prior Alkylator Exposure Impacts the Efficacy of Melflufen in Multiple Myeloma

Results of a pooled analysis suggest that melflufen plus dexamethasone is active in patients with relapsed or refractory multiple myeloma who were exposed to prior alkylators.

Cancer Therapy Advisor
09/14/2021
Microparticles and PD1 Interplay Added a Prognostic Impact in Treatment Outcomes of Patients With Multiple Myeloma

Study investigators examine the expression of PD1 and different microparticles in MM and their interplay as a mechanism of resistance to standardized treatments...

Scientific Reports
09/03/2021
Role of Whole-Body Diffusion-Weighted Imaging in Evaluation of Multiple Myeloma

This study retrospectively investigates whole-body diffusion-weighted imaging in the evaluation of bone marrow infiltration and treatment response in multiple myeloma.

Medicine
09/03/2021
Addition of Venetoclax to Daratumumab/Dexamethasone With or Without Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Investigators find that venetoclax plus daratumumab/dexamethasone and VenDd with bortezomib produce high rates of durable responses in patients with R/R MM with...

The ASCO Post
09/02/2021
Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma

Immunotherapy based on CAR-T therapy has achieved success in the treatment of hematological malignant tumors. Investigators successfully constructed two novel second-generation...

Frontiers in Oncology
08/26/2021
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

This phase I study evaluates venetoclax with daratumumab and dexamethasone in patients with t(11;14) RRMM and VenDd with bortezomib in cytogenetically unselected patients with RRMM.

Journal of Clinical Oncology
08/13/2021
Teclistamab Shows Efficacy, Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

Study investigators find that the BCMA-CD3 bispecific antibody teclistamab produces a high rate of durable responses at the recommended phase II dose in patients with R/R MM.

The ASCO Post
08/16/2021
Bispecific Antibodies Advance in Relapsed or Refractory Multiple Myeloma

Early clinical trials data suggest bispecific antibodies may help meet this need, as suggested by studies presented at the 2021 ASCO Annual Meeting for talquetamab, teclistamab, and elranatamab.

The ASCO Post
08/10/2021
BCMA-Directed CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma

In the phase Ib/II CARTITUDE-1 trial reported in The Lancet, Dr Berdeja and colleagues found that ciltacabtagene autoleucel produced a high rate of durable and deep responses...

The ASCO Post
07/09/2021
Study Finds Response to COVID-19 Vaccination Varies Widely in Patients With Multiple Myeloma

Patients with MM had a wide variety of responses to COVID-19 vaccines—in some cases, no detectable response at all—pointing to the need for antibody testing and precautions...

The ASCO Post
07/09/2021
Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression

Study investigators define incidence and risk factors of ONJ and explore oral microbial signatures and host immune response as reflected by cytokine changes in saliva and serum in MM patients...

Frontiers in Oncology
06/24/2021
SMAD1 as a Biomarker and Potential Therapeutic Target in Drug-Resistant Multiple Myeloma

Study investigators aim to examine if SMAD1 plays an important role in multiple myeloma pathogenesis and can serve as a therapeutic target.

Biomarker Research
06/16/2021
Overall Survival Benefit With Upfront Daratumumab Plus Lenalidomide/Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma

The addition of daratumumab to lenalidomide and dexamethasone result in a statistically significant OS benefit over lenalidomide/dexamethasone alone in patients with newly diagnosed MM who are inel

The ASCO Post
06/15/2021
Mobile Wearable Devices Show Some Sleep Disturbances During Multiple Myeloma Treatment

In a prospective study, mobile wearable devices showed no significant gains or losses in overall sleep trends over time among patients receiving treatment for multiple myeloma.

Cancer Therapy Advisor
06/16/2021
Iberdomide-Based Regimens Show Promise in Relapsed/Refractory Multiple Myeloma

Among heavily pretreated patients with R/R MM, iberdomide-based regimens appear to yield promising safety and efficacy outcomes, supporting further study of this therapy, per research presented at

Cancer Therapy Advisor
06/13/2021
As Novel Therapies for Newly Diagnosed Multiple Myeloma Emerge, Researchers Question the Value of Standard-of-Care Autologous Stem Cell Transplant

These findings, presented during the 2021 ASCO Annual Meeting, call into question the advantages of the upfront ASCT approach in newly diagnosed MM.

ASCO Daily News
06/09/2021
CHEK1 and circCHEK1_246aa Evoke Chromosomal Instability and Induce Bone Lesion Formation in Multiple Myeloma

Multiple myeloma is still incurable and characterized by clonal expansion of plasma cells in the bone marrow.

Molecular Cancer
06/05/2021
The Influence of High-Efficiency Particulate Air Filtration on Mortality Among Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Autologous stem cell transplantation continues to be the standard treatment for transplant-eligible multiple myeloma patients.

Scientific Reports
06/03/2021
Health-Related Quality of Life in Patients With Newly Diagnosed Multiple Myeloma Ineligible for Stem Cell Transplantation: Results From the Randomized Phase III ALCYONE Trial

In the phase III ALCYONE trial, D-VMP significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multipl

BMC Cancer
06/02/2021

source list reference

rgb(171, 222, 222)
#7d60d9
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
#352625
#4d4537
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
#d2093c
#8e3f1c
rgb(242, 0, 137)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
#c61417
rgb(156, 242, 7)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(80, 147, 199)
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
#a60538
rgb(2, 230, 230)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834